Riik: Euroopa Liit
keel: inglise
Allikas: EMA (European Medicines Agency)
decitabine
Janssen-Cilag International N.V.
L01BC08
decitabine
Antineoplastic agents
Leukemia, Myeloid
Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.
Revision: 16
Authorised
2012-09-20
22 B. PACKAGE LEAFLET 23 PACKAGE LEAFLET: INFORMATION FOR THE USER DACOGEN 50 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION decitabine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dacogen is and what it is used for 2. What you need to know before you use Dacogen 3. How to use Dacogen 4. Possible side effects 5. How to store Dacogen 6. Contents of the pack and other information 1. WHAT DACOGEN IS AND WHAT IT IS USED FOR WHAT DACOGEN IS Dacogen is an anti-cancer medicine. It contains the active substance ‘decitabine’. WHAT DACOGEN IS USED FOR Dacogen is used to treat a type of cancer called ‘acute myeloid leukaemia’ or ‘AML’. This is a type of cancer that affects your blood cells. You will be given Dacogen when you are first diagnosed with AML. It is used in adults. HOW DACOGEN WORKS Dacogen works by stopping cancer cells from growing. It also kills cancer cells. Talk to your doctor or nurse if you have any questions about how Dacogen works or why this medicine has been prescribed for you. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DACOGEN DO NOT USE DACOGEN if you are allergic to decitabine or any of the other ingredients of this medicine (listed in section 6). if you are breast-feeding. If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Dacogen. WARNINGS AND PRECAUTIONS Talk to your doctor, pharmacist or nurse before using Dacogen if you have low numbers of platelets, red blood cells or white Lugege kogu dokumenti
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1 NAME OF THE MEDICINAL PRODUCT Dacogen 50 mg powder for concentrate for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of powder for concentrate for solution for infusion contains 50 mg decitabine. After reconstitution with 10 ml of water for injections, each ml of concentrate contains 5 mg of decitabine. Excipients with known effect Each vial contains 0.29 mmol sodium (E524). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for concentrate for solution for infusion (powder for infusion). White to almost white lyophilized powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dacogen is indicated for the treatment of adult patients with newly diagnosed _de novo_ or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Dacogen administration must be initiated under the supervision of physicians experienced in the use of chemotherapeutic medicinal products. Posology In a treatment cycle, Dacogen is administered at a dose of 20 mg/m 2 body surface area by intravenous infusion over 1 hour repeated daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle). The total daily dose must not exceed 20 mg/m 2 and the total dose per treatment cycle must not exceed 100 mg/m 2 . If a dose is missed, treatment should be resumed as soon as possible. The cycle should be repeated every 4 weeks depending on the patient's clinical response and observed toxicity. It is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial remission may take longer than 4 cycles to be obtained. Treatment may be continued as long as the patient shows response, continues to benefit or exhibits stable disease, i.e., in the absence of overt progression. If after 4 cycles, the patient’s haematological values (e.g., platelet counts or abs Lugege kogu dokumenti